<DOC>
	<DOCNO>NCT00085748</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability flexible dosage paliperidone ER compare placebo patient schizophrenia 65 year age old . The primary objective open-label extension long-term assessment safety tolerability paliperidone ER patient diagnose schizophrenia .</brief_summary>
	<brief_title>Safety Study With Paliperidone ER Extended-Release ( ER ) Tablets Geriatric Patients With Schizophrenia</brief_title>
	<detailed_description>Paliperidone develop new therapeutic agent treatment schizophrenia . The ER formulation paliperidone develop deliver paliperidone relatively constant rate 24-hour period improve tolerability profile decrease potential orthostatic hypotension . Typically , elderly person schizophrenia respond well antipsychotic drug . However , medication administer cautiously usually low start dosage prescribe young patient , care take balance efficacy tolerability . Flexible dosage paliperidone ER chosen study well achieve balance closely mimic clinical practice . This multicenter , double-blind ( neither patient physician know placebo drug give dose ) , randomize ( patient assign different treatment group base solely chance ) , placebo-controlled , parallel-arm study . The primary purpose study evaluate safety tolerability flexible dose paliperidone ER patient schizophrenia 65 year age old . The study consist screen phase 5 day , 6-week double-blind treatment phase , optional 24-week open-label treatment phase . For administrative purpose , screen double-blind treatment phase refer R076477-SCH-302 open-label treatment phase name R076477-SCH-702 . Patients randomly assign receive paliperidone ER placebo . At time patient enter double-blind period , must hospitalize minimum 14 full day . Those patient receive paliperidone ER start dosage 6 mg take daily , may titrate maximum 12 mg minimum 3 mg daily base patient 's safety tolerability drug . Patients complete 6 week double-blind treatment , finish least 21 day treatment discontinue lack efficacy , may enter 24-week open label treatment phase . While patient hospitalize , efficacy assess twice first week end second week . Efficacy evaluate throughout 6-week double-blind phase completion Positive Negative Syndrome Scale ( PANSS ) , Clinical Global Impression Scale - Severity ( CGI-S ) , Personal Social Performance Scale ( PSP ) , Schizophrenia Quality Life Scale , Revision 4 ( SQLS-R4 ) , Sleep Visual Analog Scale ( VAS ) double-blind treatment phase . The efficacy variable measure change baseline score PANSS , CGI S , SQLS-R4 , Sleep VAS , PSP . Safety monitor throughout study base incidence adverse event ; measurement extrapyramidal symptom use 3 rating scale ( Abnormal Involuntary Movement Scale [ AIMS ] , Barnes Akathisia Rating Scale [ BARS ] , Simpson-Angus Rating Scale [ SAS ] ) ; measurement vital sign ( blood pressure , heart rate ) ; electrocardiogram ; clinical laboratory test . Double-blind phase : paliperidone ER flexibly dose range 3 12 mg ( 3 , 6 , 9 , 12 mg/day ) orally day match placebo , 6 week . Open-label phase : The start dose 6 mg/day 7 day ; thereafter , flexible oral dosage paliperidone ER ( 3 , 6 , 9 , 12 mg/day ) 24 week .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>DoubleBlind Phase : 65 year age old DSMIV diagnosis schizophrenia least 1 year total PANSS score screen baseline 70 120 , inclusive agrees hospitalization minimum 14 day duration study , clinically indicated Openlabel treatment phase : complete 6 week doubleblind treatment phase finish least 21 day treatment discontinue lack efficacy . DSMIV Axis I diagnosis schizophrenia DSMIV diagnosis substance dependence within 6 month screen ( nicotine caffeine dependence exclusionary ) history tardive dyskinesia neuroleptic malignant syndrome ( NMS ) history severe preexist severe gastrointestinal narrowing ( pathologic iatrogenic ) previous history lack response ( 2 adequate trial ) antipsychotic</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>geriatric</keyword>
	<keyword>elderly</keyword>
</DOC>